In the News
Self-monitoring of blood glucose reduced HbA1c in noninsulin-treated patients
Self-monitoring of blood glucose 8 to 11 times a week was more effective than doing so more or less frequently, according to a new meta-analysis.
HbA1c-based screening of general population reduced time to diabetes diagnosis
In a British database, 1% of participants ages 40 to 70 years had undiagnosed diabetes. Researchers estimated that population-based screening using HbA1c level could have reduced the time to diagnosis in this group by a median of 2.2 years.
Updated guideline on managing hyperosmolar hyperglycemic state issued by U.K. experts
The recommendations from the Joint British Diabetes Societies for Inpatient Care Group cover clinical assessment and monitoring, interventions, and assessments and prevention of harm, as well as five phases of therapy.
MKSAP quiz: Screening during pregnancy
This month's quiz asks readers to evaluate a 28-year-old woman following a positive pregnancy test. She has polycystic ovary syndrome, and her mother has diabetes.
Spotlight on resistance training
Several recent studies found modest benefits to patients with type 1 or type 2 diabetes participating in strengthening exercises.
GLP-1 receptor agonists associated with thyroid cancer
Patients taking a glucagon-like peptide-1 (GLP-1) receptor agonist had about one and a half times the risk of developing thyroid cancer compared to similar controls, according to an observational French study.
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
California's insulin plan, clinical decision support in lower-income countries
Recent articles from Annals of Internal Medicine discussed California's plan to produce insulin and a diabetes clinical decision support system that may be helpful in primary care in low- to middle-income countries.
BP-lowering drugs reduced major CV events by similar amounts in patients with and without type 2 diabetes
The results of a large meta-analysis support the conclusion that degree of blood pressure (BP) lowering, rather than the drug used, is the prime driver of cardiovascular (CV) risk reduction from hypertension therapy, an ACP Journal Club commentary said.
Diabetes device recalled due to risk of fire
The FDA recently announced a class I recall of the Omnipod DASH Insulin Management System Personal Diabetes Manager due to reports of battery issues, including battery swelling, fluid leakage, and extreme overheating that may pose a fire hazard.
Drug approved to delay onset of stage 3 type 1 diabetes
The first-in-class therapy, indicated in adults and pediatric patients ages 8 years and older who currently have stage 2 type 1 diabetes, is administered by IV infusion once daily for 14 consecutive days.